Showing 121 results
November 2022
-
Media Release
Novartis partners with DOH, medical societies, hospitals to strengthen healthcare system and improve heart failure management in PH
In a developing country like the Philippines, where healthcare delivery is mostly paid through patients' out-of-pocket expenses, the economic burden of heart failure (HF), especially… -
Media Release
Novartis recognized for supporting eye health services amid pandemic
Novartis Healthcare Philippines was recognized by the National Committee for Sight Preservation (NCSP) for the company’s support to the NCSCP “Maging MATAlino”…
August 2022
-
Media Release
Alliance and Partnerships for Patient Innovation and Solutions (APPIS) Initiative announces winners of inaugural Innovator Program
The APPIS Innovator Program enables patient organizations across Asia Pacific, Middle East and Africa (APMA) to grow and scale existing patient programs. Winners receive financial support,… -
Media Release
Novartis hails Philippine FDA approval of brolucizumab treatment for age-related macular degeneration in time for Sight Saving Month
The Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD). Wet AMD is the leading cause of severe…
July 2022
-
Media Release
Novartis, Ask Your Derm PH raise awareness on pediatric psoriasis and effective treatments to help children manage symptoms, enjoy life
Psoriasis causes significant physical, emotional and psychological burden on children and adolescents. Fortunately, effective treatment options are available and parents can take steps to help… -
Media Release
Experts encourage women with advanced breast cancer to get tested for PIK3CA mutation to improve treatment outcomes
Genetic mutations affect breast cancer prognosis, making every patient unique. It is important for patients to get tested to find out the specific mutation, and help doctors develop a personalized… -
Media Release
Philippine FDA approves Novartis advanced breast cancer treatment, alpelisib
The Philippine Food and Drug Administration (FDA) has approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human…